How is the Anaplastic Astrocytoma Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the anaplastic astrocytoma market size evolved in recent years?
Recent years have witnessed a robust growth in the market size of anaplastic astrocytoma. The market, which stands at $0.44 billion in 2024 is projected to expand to $0.47 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.8%. This upward trend during the historic period can be credited to the increased use of targeted therapies, heightened patient advocacy and awareness, expansion of clinical trials, advancements in healthcare policy and funding, along with supportive government initiatives.
What are the predictions for the anatomical models market size in the coming years?
Expectations indicate a significant rise in the anaplastic astrocytoma market size in the coming years. The market is projected to expand to $0.62 billion in 2029, with a compound annual growth rate (CAGR) of 7.0%. This growth through the forecast period can be linked to factors such as the upswing in research and development activities, the increasing demand for personalized medicine, amplified investments, enhanced disease awareness, and a rise in stress and depression. The forecast period will also witness certain major trends such as progression in neurosurgery, advancements in radiation therapy, extensive clinical trials and research, the embracing of telemedicine and remote monitoring technologies, and significant developments in imaging, biotechnology, and drug development.
Get your anaplastic astrocytoma market report here!
https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report
What key factors are fueling the growth of the anaplastic astrocytoma market?
The anaplastic astrocytoma market is set to experience growth due to the escalating occurrence of primary malignant and benign brain tumours. Brain tumours, which can either be benign (non-cancerous) and non-invasive, or malignant (cancerous) and invasive, vary in their degree of aggressiveness and ability to proliferate. The treatment of anaplastic astrocytoma involves the extraction of the tumour and the adjacent affected tissue, while preserving the brain’s functionality. As per the American Society of Clinical Oncology (ASCO), a non-profit organization in the U.S., it’s forecasted that around 24,810 adults in the country will be diagnosed with primary cancerous tumours originating from the brain and the spinal cord in March 2023. Of this number, men account for 14,280 cases while women consist of 10,530 cases. Accordingly, the rising occurrence of primary malignant and benign brain tumours is set to fuel the expansion of the anaplastic astrocytoma market in the future.
Anaplastic Astrocytoma Market Driver: Anaplastic Astrocytoma Market to Benefit from Government Funding
How is the global anaplastic astrocytoma market divided into key segments?
The anaplastic astrocytoma market covered in this report is segmented –
1) By Disease Type: Grade I, Grade II, Grade III, Grade IV
2) By Treatment Type: Surgery, Chemotherapy, Radiation
3) By Treatment Phase: Pre-Registration Phase, Clinical Trial Phase
4) By End-User: Hospitals And Clinics, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Grade I: Pilocytic Astrocytoma
2) By Grade II: Diffuse Astrocytoma, Oligodendroglioma
3) By Grade III: Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
4) By Grade IV: Glioblastoma Multiforme (GBM), Primary Glioblastoma, Secondary Glioblastoma
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12874&type=smp
Who are the key firms paving the way for growth in the anaplastic astrocytoma market?
Major companies operating in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Perrigo Company PLC, Ipsen SA, Genentech Inc., Cipla Limited, Novocure Ltd., Celon Laboratories Limited, Avid Bioservices Inc., EirGen Pharma Ltd., Monteris Medical Corporation, GLS Pharma Pvt. Ltd., Tocagen Inc., Pharma’s Almanac, Inovio Pharmaceuticals Inc., Isarna Therapeutics GmbH, Actiza Pharmaceutical Private Limited, Celldex Therapeutics Inc.
Which trends are expected to transform the anaplastic astrocytoma market?
Leading organizations in the anaplastic astrocytoma sector are advancing new treatment methods to elevate effectiveness, reduce adverse effects and enhance patient results. For example, in June 2022, the U.S. Food and Drug Administration, a federal body in the U.S., provided fast-track approval for an innovative treatment blend including the oral drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for sophisticated brain tumors with the BRAF V600E mutation. This endorsement pertains to adult and pediatric patients with high- and low-grade gliomas that have developed after previous treatment. The BRAF V600E mutation is common in various glioma kinds, encompassing low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytoma. This consent was grounded on clinical studies for the Tafinlar-Mekinist combined therapy that resulted in benefits in tumor reduction for both adult and pediatric glioma patients, with a 33% response rate noted in high-grade glioma patients, a 50% response rate in low-grade glioma patients and a 25% response rate in pediatric glioma patients.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12874
What regions are contributing significantly to the growth of the anaplastic astrocytoma market?
North America was the largest region in the anaplastic astrocytoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anaplastic astrocytoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Generic Central Nervous System Drugs Global Market Report 2024
Central Nervous System Biomarkers Global Market Report 2024
Neurophysiology Devices And Equipment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
